Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut d… Read more
Market Cap & Net Worth: Pieris Pharmaceuticals Inc (PIRS)
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has a market capitalization of $17.96 Million ($17.96 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28114 globally and #9384 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pieris Pharmaceuticals Inc's stock price $13.60 by its total outstanding shares 1320240 (1.32 Million).
Pieris Pharmaceuticals Inc Market Cap History: 2015 to 2024
Pieris Pharmaceuticals Inc's market capitalization history from 2015 to 2024. Data shows change from $241.87 Million to $17.96 Million (-23.21% CAGR).
Index Memberships
Pieris Pharmaceuticals Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2361 of 3165 |
Weight: Pieris Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pieris Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pieris Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.45x
Pieris Pharmaceuticals Inc's market cap is 0.45 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $241.87 Million | $2.93 Million | -$14.06 Million | 82.49x | N/A |
| 2016 | $148.42 Million | $5.83 Million | -$22.80 Million | 25.45x | N/A |
| 2017 | $797.42 Million | $25.27 Million | -$17.65 Million | 31.55x | N/A |
| 2018 | $280.95 Million | $29.10 Million | -$26.75 Million | 9.65x | N/A |
| 2019 | $382.34 Million | $46.28 Million | -$23.75 Million | 8.26x | N/A |
| 2020 | $264.05 Million | $29.32 Million | -$37.23 Million | 9.00x | N/A |
| 2021 | $399.24 Million | $31.42 Million | -$43.37 Million | 12.71x | N/A |
| 2022 | $109.84 Million | $25.90 Million | -$31.25 Million | 4.24x | N/A |
| 2023 | $19.22 Million | $42.81 Million | -$24.54 Million | 0.45x | N/A |
Competitor Companies of PIRS by Market Capitalization
Companies near Pieris Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Pieris Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Pieris Pharmaceuticals Inc Historical Marketcap From 2015 to 2024
Between 2015 and today, Pieris Pharmaceuticals Inc's market cap moved from $241.87 Million to $ 17.96 Million, with a yearly change of -23.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $17.96 Million | -6.59% |
| 2023 | $19.22 Million | -82.50% |
| 2022 | $109.84 Million | -72.49% |
| 2021 | $399.24 Million | +51.20% |
| 2020 | $264.05 Million | -30.94% |
| 2019 | $382.34 Million | +36.09% |
| 2018 | $280.95 Million | -64.77% |
| 2017 | $797.42 Million | +437.29% |
| 2016 | $148.42 Million | -38.64% |
| 2015 | $241.87 Million | -- |
End of Day Market Cap According to Different Sources
On Dec 12th, 2025 the market cap of Pieris Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.96 Million USD |
| MoneyControl | $17.96 Million USD |
| MarketWatch | $17.96 Million USD |
| marketcap.company | $17.96 Million USD |
| Reuters | $17.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.